SkinBioTherapeutics plc (FRA:5KW)

Market Cap	15.43M -68.8%
Revenue (ttm)	5.41M +283.7%
Net Income	-812.25K
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	n/a
Open	0.0405
Previous Close	0.0410
Day's Range	0.0405 - 0.0405
52-Week Range	0.0405 - 0.3120
Beta	n/a
RSI	16.28
Earnings Date	Mar 25, 2026

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with...

• Industry: Perfumes, Cosmetics, and Other Toilet Preparations
• Founded: 2015
• Employees: 41
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5KW

Financial Performance

In fiscal year 2025, SkinBioTherapeutics's revenue was 4.64 million, an increase of 283.74% compared to the previous year's 1.21 million. Losses were -696,253, -75.79% less than in 2024.

Financial numbers in GBP